Literature DB >> 30269490

DARK Classics in Chemical Neuroscience: Aminorex Analogues.

Julian Maier1, Felix P Mayer1, Simon D Brandt2, Harald H Sitte1.   

Abstract

Aminorex (5-phenyl-4,5-dihydro-1,3-oxazol-2-amine) and 4-methylaminorex (4-methyl-5-phenyl-4,5-dihydro-1,3-oxazol-2-amine) are psychostimulants that have long been listed in Schedules IV and I of the UN Convention on Psychotropic Substances of 1971. However, a range of psychoactive analogues exist that are not internationally controlled and therefore often classified as new psychoactive substances (NPS). Aminorex analogues encompass failed pharmaceuticals that reemerged as drugs of abuse, and newly synthesized substances that were solely designed for recreational use by clandestine chemists. NPS, sometimes also referred to as "designer drugs" in alignment with a phenomenon arising in the early 1980s, serve as alternatives to controlled drugs. Aminorex and its derivatives interact with monoaminergic neurotransmission by interfering with the function of monoamine transporters. Hence, these compounds share pharmacological and neurochemical similarities with amphetamines and cocaine. The consumption of aminorex, 4-methylaminorex and 4,4'-dimethylaminorex (4-methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine) has been associated with adverse events including death, bestowing an inglorious fame on aminorex-derived drugs. In this Review, a historical background is presented, as well as an account of the pharmacodynamic and pharmacokinetic properties of aminorex and various analogues. Light is shed on their misuse as drug adulterants of well-established drugs on the market. This Review not only provides a detailed overview of an abused substance-class, but also emphasizes the darkest aspect of the NPS market, i.e., deleterious side effects that arise from the ingestion of certain NPS, as knowledge of the pharmacology, the potency, or the identity of the active ingredients remains obscure to NPS users.

Entities:  

Keywords:  Psychostimulants; aminorex; drug abuse; levamisole; monoamine transporters; new psychoactive substances

Mesh:

Substances:

Year:  2018        PMID: 30269490      PMCID: PMC6287711          DOI: 10.1021/acschemneuro.8b00415

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   5.780


  186 in total

1.  Cyclosporin combined with levamisole for refractory or relapsed severe aplastic anaemia.

Authors:  Yingqi Shao; Xingxin Li; Jun Shi; Meili Ge; Jinbo Huang; Zhendong Huang; Jing Zhang; Neng Nie; Yizhou Zheng
Journal:  Br J Haematol       Date:  2013-05-23       Impact factor: 6.998

Review 2.  From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs.

Authors:  Hamilton Morris; Jason Wallach
Journal:  Drug Test Anal       Date:  2014-03-26       Impact factor: 3.345

3.  Aminorex associated with possible idiopathic pulmonary hypertension in a cocaine user.

Authors:  Steven B Karch; Beatrice Defraia; Luca Messerini; Francesco Mari; Fabio Vaiano; Elisabetta Bertol
Journal:  Forensic Sci Int       Date:  2014-04-06       Impact factor: 2.395

4.  Pharmacological characterization of designer cathinones in vitro.

Authors:  L D Simmler; T A Buser; M Donzelli; Y Schramm; L-H Dieu; J Huwyler; S Chaboz; M C Hoener; M E Liechti
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

5.  Metabolism of 4-methylaminorex ("EU4EA") in the rat.

Authors:  G L Henderson; M R Harkey; Y T Chueh
Journal:  J Anal Toxicol       Date:  1995 Nov-Dec       Impact factor: 3.367

6.  Stimulus properties of some analogues of 4-methylaminorex.

Authors:  B R Russell; R A Beresford; D M Schmierer; N McNaughton; C R Clark
Journal:  Pharmacol Biochem Behav       Date:  1995 Jun-Jul       Impact factor: 3.533

7.  Long term effects of the anorectic agent fenfluramine alone and in combination with aminorex on pulmonary and systemic circulation in the pig.

Authors:  J Mlczoch; E K Weir; J T Reeves; R F Grover
Journal:  Basic Res Cardiol       Date:  1979 May-Jun       Impact factor: 17.165

8.  Membranous glomerulonephritis and cellular crescents induced by levamisole-adulterated cocaine abuse: a case report.

Authors:  Lourdes Roca-Argente; Jose-Luis Moll-Guillen; Jordi Espí-Reig; Marino Blanes-Julia; Ana-María García-Martínez; Conrad Pujol-Marco; Julio Hernández-Jaras
Journal:  Ann Transl Med       Date:  2015-10

9.  Anthelmintic Drugs: Their Efficacy and Cost-Effectiveness in Different Parity Cattle.

Authors:  Muhammad Saqib Ali; Khalid Saeed; Imran Rashid; Muhammad Ijaz; Haroon Akbar; Muhammad Rashid; Kamran Ashraf
Journal:  J Parasitol       Date:  2017-11-08       Impact factor: 1.276

10.  Necrotizing and crescentic glomerulonephritis with membranous nephropathy in a patient exposed to levamisole-adulterated cocaine.

Authors:  Camillo Carrara; Stefano Emili; Mercury Lin; Charles E Alpers
Journal:  Clin Kidney J       Date:  2015-12-28
View more
  6 in total

Review 1.  Interpol review of controlled substances 2016-2019.

Authors:  Nicole S Jones; Jeffrey H Comparin
Journal:  Forensic Sci Int Synerg       Date:  2020-05-24

2.  Genotoxicological Characterization of (±)cis-4,4'-DMAR and (±)trans-4,4'-DMAR and Their Association.

Authors:  Monia Lenzi; Sofia Gasperini; Veronica Cocchi; Micaela Tirri; Matteo Marti; Patrizia Hrelia
Journal:  Int J Mol Sci       Date:  2022-05-23       Impact factor: 6.208

Review 3.  The Interaction of Organic Cation Transporters 1-3 and PMAT with Psychoactive Substances.

Authors:  Julian Maier; Marco Niello; Deborah Rudin; Lynette C Daws; Harald H Sitte
Journal:  Handb Exp Pharmacol       Date:  2021

4.  Characterization of a recently detected halogenated aminorex derivative: para-fluoro-4-methylaminorex (4'F-4-MAR).

Authors:  D Fabregat-Safont; X Carbón; M Ventura; I Fornís; F Hernández; M Ibáñez
Journal:  Sci Rep       Date:  2019-06-05       Impact factor: 4.379

5.  Interaction Profiles of Central Nervous System Active Drugs at Human Organic Cation Transporters 1-3 and Human Plasma Membrane Monoamine Transporter.

Authors:  Thomas J F Angenoorth; Stevan Stankovic; Marco Niello; Marion Holy; Simon D Brandt; Harald H Sitte; Julian Maier
Journal:  Int J Mol Sci       Date:  2021-11-30       Impact factor: 6.208

Review 6.  Designer drugs: mechanism of action and adverse effects.

Authors:  Dino Luethi; Matthias E Liechti
Journal:  Arch Toxicol       Date:  2020-04-06       Impact factor: 5.153

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.